ESWT For Plantar Fasciitis: What Do The Long-Term Results Reveal?
- Volume 24 - Issue 11 - November 2011
- 21374 reads
- 3 comments
The indirect costs associated with surgical intervention include the chance of significant complications requiring some intervention (2 to 5 percent) and the resultant expense of care needed for those complications. Other indirect costs associated with open surgery include lost time from work and changes in activities of daily living. It is not uncommon for postoperative plantar fasciitis patients to miss work for two to six weeks due to immobilization and partial weightbearing. It is difficult to accurately determine the overall cost of someone being away from work as this is different from person to person based on the job. It is even more difficult to put a number on the cost of interference in activities of daily life. Without doubt, there are tangible dollars and social costs that are significant with both.
With low-energy ESWT, the typical costs range from $900 to $1,500 total for three treatments, based on my experience and talking to people around the country, and recognizing what insurance covers when ESWT is covered. There is no facility fee or anesthesia fee. There are no complications associated with low-energy ESWT that would create any additional expenses. There is virtually no loss of work with the exception of the time spent to have the procedure performed. Social costs are also reduced as patients can return to almost all activities of daily life without restrictions.
High-energy shockwave does have higher costs associated with it in comparison to low-energy ESWT and can range from $1,000 to $3,000 total. However, treatment with high-energy ESWT does have the advantage of one-time treatment.
Extracorporeal shockwave therapy, high energy or low energy, exhibits strong cost benefits in both absolute dollars and less tangible but equally important work and social costs. The Journal of Bone and Joint Surgery states that long-term studies must be those that have been performed at least five years following the original study. We initially reported our early results in 2002 in the Journal of Foot and Ankle Surgery and now have reported our long-term results, which, as far as we know, is the only long-term study on ESWT and plantar fasciitis.4,5
Extracorporeal shockwave therapy has gone through the trials and tribulations of being a new and expensive technology. These include inconsistent information to consumers, conflicting results of research on the efficacy of the technology and the relative inaccessibility to physicians and patients. However, years of clinical success and proper research have proved the validity of ESWT.
Plantar fasciitis continues to be a burden on our healthcare system, economy and society. It is incumbent on all medical providers to find the most proven and cost-effective treatments for their patients to return to life and work. While there are many treatments employed for plantar fasciitis, most have not been proven and we have pointed out their costs. Others have been studied but their costs are quite substantial and their complications are notable.
Extracorporeal shockwave therapy has proven to be a cost effective treatment for plantar fasciitis while showing long-term success that other treatments cannot boast. Not only should one consider ESWT a mainstay of treatment for more chronic cases of plantar fasciitis, it should now be an option earlier in the treatment regimen and possibly supplant other treatments that have not been validated. The future may show that combining treatments such as ESWT and PRP will provide the fastest and safest recovery but until PRP is better studied, it will still take a back seat to ESWT.
Dr. Weil is the Research and Fellowship Director for the Weil Foot and Ankle Institute, which has various office locations in Illinois. He is the Editor of Foot and Ankle Specialist, and is a Past President of the International Society for Medical Shockwave Treatment.